Amgen Inc. (NASDAQ:AMGN) Stock Holdings Decreased by Measured Wealth Private Client Group LLC

Measured Wealth Private Client Group LLC lessened its position in Amgen Inc. (NASDAQ:AMGN) by 25.8% in the 3rd quarter, Holdings Channel reports. The fund owned 901 shares of the medical research company’s stock after selling 314 shares during the period. Measured Wealth Private Client Group LLC’s holdings in Amgen were worth $290,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. Hershey Financial Advisers LLC purchased a new stake in shares of Amgen in the second quarter valued at $30,000. nVerses Capital LLC purchased a new stake in Amgen in the 2nd quarter worth about $31,000. Bbjs Financial Advisors LLC acquired a new stake in Amgen during the 2nd quarter worth about $33,000. Matrix Trust Co purchased a new position in Amgen during the 3rd quarter valued at about $36,000. Finally, FSA Wealth Management LLC increased its holdings in shares of Amgen by 182.0% in the 1st quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock valued at $40,000 after purchasing an additional 91 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 1.0 %

Shares of NASDAQ AMGN opened at $318.83 on Thursday. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. The company has a market cap of $171.03 billion, a PE ratio of 45.08, a P/E/G ratio of 2.86 and a beta of 0.61. The company has a 50-day moving average of $324.75 and a two-hundred day moving average of $314.78. Amgen Inc. has a 1-year low of $249.70 and a 1-year high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. During the same quarter in the prior year, the company earned $4.96 EPS. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. As a group, equities analysts expect that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be issued a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 2.82%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s payout ratio is 128.57%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AMGN. Bank of America lifted their target price on shares of Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Cantor Fitzgerald restated an “overweight” rating and issued a $405.00 target price on shares of Amgen in a research note on Tuesday, October 22nd. Sanford C. Bernstein initiated coverage on Amgen in a research note on Thursday, October 17th. They set an “outperform” rating and a $380.00 price target for the company. Morgan Stanley lowered their price target on Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research note on Thursday, July 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 price objective (up previously from $375.00) on shares of Amgen in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $332.55.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.